Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Assets (2016 - 2025)

Lexaria Bioscience's Current Assets history spans 11 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Current Assets fell 39.23% year-over-year to $5.4 million; the TTM value through Nov 2025 reached $5.4 million, down 39.23%, while the annual FY2025 figure was $3.5 million, 56.09% down from the prior year.
  • Current Assets for Q4 2025 was $5.4 million at Lexaria Bioscience, up from $3.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $12.4 million in Q3 2021 and bottomed at $2.2 million in Q3 2023.
  • The 5-year median for Current Assets is $7.4 million (2022), against an average of $7.1 million.
  • The largest annual shift saw Current Assets soared 827.62% in 2021 before it plummeted 69.17% in 2023.
  • A 5-year view of Current Assets shows it stood at $10.9 million in 2021, then crashed by 50.84% to $5.4 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then skyrocketed by 227.65% to $8.8 million in 2024, then crashed by 39.23% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Current Assets are $5.4 million (Q4 2025), $3.5 million (Q3 2025), and $5.8 million (Q2 2025).